RMG Acquisition Corp. (RMG.U) Files for $200 SPAC IPO
by Kristi Marvin on 2018-12-17 at 5:07pm

This afternoon, Deutsche Bank filed their second January SPAC with RMG Acquisition Corp. (RMG.U), a $200 million IPO focused on the diversified resources and industrial materials sectors. RMG will be led by Robert S. Mancini, as CEO and Director, and D. James Carpenter, as Chairman.

Mr. Mancini is the former Senior Advisor to Carlyle Power Partners and was a Partner and a Managing Director with The Carlyle Group and head or co-head of Carlyle’s power investment business. Additionally, he was a former Managing Director at Goldman Sachs, where he was instrumental in the formation of Goldman’s entry into the power asset investment business and was also responsible for the creation of Goldman’s proprietary Commodities Principal Investment business.  So the guy knows his stuff.

Rounding out the executive team is Phil Kassin, who will be President, COO and Director. Mr. Kassin brings the always appreciated prior SPAC experience having been the former Managing Director and Head of M&A and Financing at M-III Partners, which sponsored the $345 million SPAC, M-III Acquisition Corp.  Mr. Kassin completed M-III’s acquisition of Infrastructure and Energy Alternatives (NASDAQ: IEA) from Oaktree Capital Management earlier this year.

Looking at RMG’s terms, this is a tier-1 structure and as such, they’re asking for 24 months, 1/3 warrant and 100% in trust.  However, there isn’t any forward purchase arranged or any fancy terms like the warrant call for shares at $10.00.  Nonetheless, we now have two SPACs on file with management-friendly terms to counteract the investor-friendly terms we’ve been seeing of late.  Balance is always good for SPACs in general, so this is a positive.

To date, we have four SPACs on file for 2019 with a potential $825 million in gross proceeds and it’s only December 17th.  We expect to see a few more SPACs get filed this month to tee-up January, so hang on to your hats.  No rest for anyone in SPAC-land.

Summary of terms below:

RMG Acquisition Terms

Deutsche Banks is sole bookrunning manager.
Latham & Watkins LLP and Weil, Gotshal & Manges LLP are issuer’s counsel and underwriter’s counsel, respectively.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved